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A B S T R A C T
Phytoestrogen-based medications are commonly used by menopausal women, and especially by obese post-
menopausal women, to relieve menopausal symptoms. Substitution of animal with soy protein is often used in
weight loss regimens, yet the effect of phytoestrogens, the main constituent of soy foods, on body composition is
not completely understood. We conducted a systematic review and meta-analysis to investigate the associations
between phytoestrogen supplementation and body weight and the main parameters of body composition in
postmenopausal women. A literature search was done using 5 electronic databases from inception to April 2018.
Randomized controlled trials (RCTs) with postmenopausal women comparing phytoestrogen supplementation
followed by usual diet and placebo were included in the present meta-analysis. From 5932 references, we
identified 23 RCTs that met our inclusion criteria, with a total of 1880 postmenopausal women. No association
was observed between phytoestrogen supplementation and body weight, body mass index, waist and hip cir-
cumference, total fat mass or percentage of body fat. However, the use of phytoestrogens supplementation was
associated with a slight decrease in waist-hip ratio; the pooled mean difference was−0.01 cm (95%CI: −0.01 to
−0.006). In subgroup analysis, we found a modest decrease in body weight with phytoestrogens supple-
mentation compared with placebo in healthy postmenopausal women [pooled mean difference of changes
−0.28 kg (95%CI: −0.52 to −0.04)] and in RCTs with a median number of participants of 66 or less [pooled
mean difference of changes −0.49 kg (95%CI: −0.87 to −0.11)]. In contrast, phytoestrogen supplementation
was associated with increased body weight in postmenopausal women with preexisting metabolic disorders
(prediabetes, type 2 diabetes, prehypertension and hyperlipidemia) [pooled mean difference of changes: 0.78 kg
(95%CI: 0.53–1.03)]. In addition, there were some indications that some types of phytoestrogens, such as
daidzein, but not soy products or isoflavone mix, could lead to modest adverse changes in body composition in
menopausal women. Therefore, future studies should investigate the potential adverse effects of phytoestrogen
supplementation on body composition among postmenopausal women.
⁎ Corresponding author at: Department of Epidemiology, Erasmus University Medical Center, Dr. Molewaterplein 50, Office NA29-09, PO Box 2040, 3000 CA Rotterdam, The
Netherlands.
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Abbreviations: BMI, body mass index; FM, fat mass; HC, hip circumference; MHT, menopausal hormone therapy; PBF, percentage of body fat; RCT, randomized controlled trial; T2D,
type 2 diabetes; WC, waist circumference; WHR, waist to hip ratio
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1. Introduction
Menopause is considered as the end of woman’s reproductive life,
generally defined as “cessation” of menstrual periods for twelve con-
secutive months [1]. Menopausal transition is characterized by hor-
monal disturbances, irregular menstrual periods and presence of me-
nopausal symptoms [1]. The most challenging menopausal symptoms
include hot flashes and night sweats, with 50.3%–82.1% of post-
menopausal reporting either mild, moderate or severe vasomotor
symptoms [2,3]. In women, aging and menopause-induced estrogen
deficiency could result in an increase in body weight and may lead to
abdominal fat accumulation and decrease in lean mass during meno-
pausal transition [4]. Overweight and obese menopausal women may
also tend to have more prevalent [8] and more severe menopausal
symptoms [5–8]. Thus, menopausal hormone therapy (MHT) remains
the most effective treatment for menopausal vasomotor symptoms [9].
However, given the potentially undesirable health consequences of
hormone therapy on cardiovascular health and breast cancer risk, the
number of women choosing plant based-therapies as an alternative to
treat menopausal symptoms is increasing [10].
The most commonly used herbal therapies may include “over the
counter” phytoestrogen supplements, such as dietary soy isoflavones
and soy extracts and herbal remedies such as red clover and black co-
hosh [10]. Phytoestrogens are a group of biologically active plant-de-
rived compounds with estrogen-like properties [11]. Isoflavones (gen-
isten and diadzein) and lignans are the most used phytoestrogens; while
isoflavones can be abundantly found in soybeans, lignans are found in
legumes, vegetables, fruits, flaxseed and whole grains [11]. Recent
meta-analysis of clinical trials showed that specific phytoestrogen
supplementation led to relief of menopausal symptoms [10]. Never-
theless, there is inconsistent evidence whether phytoestrogens could
additionally help to reduce body weight and counteract the adverse
changes that may occur in body composition in women after meno-
pause. While few studies indicated that phytoestrogens may lead to
modest improvements in body weight and the other parameters of body
composition [12–14], there were few studies raising concerns that
phytoestrogens could lead to adverse body composition changes, such
as increase in weight [15–18] and body mass index (BMI) [16,18–20].
A meta-analysis of nine randomized trials (conducted in 2013) has
suggested that isoflavone supplementation might reduce the body
weight [21]. However, this study was limited only to non-Asian post-
menopausal women and by investigating only the changes in body
weight and not the other parameters of body composition. Furthermore,
only trials that investigated solely isoflavone supplementation, and not
the other types of phytoestrogens, were included in that review.
Therefore, this comprehensive systematic review and meta-analysis
of intervention studies aimed to evaluate the association between
phytoestrogen supplementation followed with regular/normocaloric
diet and body composition in postmenopausal women.
2. Methods
2.1. Data sources and search strategy
The Cochrane Handbook for Systematic Reviews of Interventions
and PRISMA Statement were used to guide the conduct and reporting of
this review [22]. A literature search was done using 5 electronic da-
tabases (Medline via Ovid, EMBASE, Web of Science Core Collection,
Cochrane CENTRAL via Wiley and Google Scholar) from inception to
April 2018 (date last searched). Additionally, we searched the reference
lists of the included studies and relevant reviews. Details on the search
strategy are provided in Supplemental Table 1.
2.2. Study selection and data extraction
Studies were included if they met the following inclusion criteria: (i)
were randomized placebo-controlled trials (ii) reported associations of
phytoestrogen supplementation with total body weight, total fat mass
(FM), percentage of body fat (PBF), BMI, waist circumference (WC),
and waist to hip ratio (WHR), (iii) were performed among post-
menopausal women and (iv) investigated phytoestrogen supplementa-
tion in intervention arm alone. RCTs investigated combination of ex-
posures (e.g. hypocaloric diet or exercise with phytoestrogen
supplementation) were not included in this study. Additionally, as we
were interested to evaluate overall effect of phytoestrogens on body
weight (and not its effect on weight loss), we decided to include RCTs
irrespectively of the study aim; therefore, all eligible RCTs that reported
baseline and end of study information on outcomes of interest were
included in this review. Two reviewers independently evaluated the
titles and abstracts according to the inclusion and exclusion criteria. For
each potentially eligible study, two reviewers assessed the full-text. In
cases of disagreement, a decision was made by consensus or, if neces-
sary, a third reviewer was consulted. A predesigned data extraction
form was used to collect relevant information.
2.3. Assessing the risk of bias
The risk of bias within each individual study was evaluated by two
reviewers. To assess the quality of RCTs, “The Cochrane Collaboration's
tool” for assessing risk of bias was used [23]. Studies were judged to be
at lower high risk of bias based on criteria to evaluate random sequence
generation, allocation concealment, blinding of participants/personnel
and outcome assessment, incomplete outcome data and selective re-
porting [23]. RCTs were considered to be in low risk of bias, if allo-
cation concealment, blinding of participants and outcome assessors
were all coded “yes”, if a compliance assessment was done, and the
number of dropouts and reasons for dropout were reported, otherwise
the RCTs were considered to be at high risk of bias. If the risk of bias
couldn’t be determined in any of the segments (e.g. information not
provided) the risk of bias was classified as unknown (Supplemental
Table 2).
2.4. Data synthesis and analysis
Summary outcomes measures were presented as mean differences
(intervention minus control) of the treatment effects (differences in
outcomes at the end of trial) between treatment groups in body weight,
BMI, WC, HC, HC, FM and PBF. Estimates of weighted mean differences
(WMDs) and 95% CIs were obtained using random-effect model. In case
of cross-over trials, the data from the first period only were used. In
addition, for sensitivity analysis, the estimates were reported using
fixed effect models as shown in the forest plots. Heterogeneity was
quantified using the I2 statistic, classified as low (I2 ≤25%), moderate
(I2>25% and<75%), or high (I2 ≥75%) [24]. Additionally, Q-sta-
tistic was used to assess the presence of heterogeneity. PQ statistic ≥0.05
was considered to indicate no significant heterogeneity among the in-
cluded studies. Study characteristics including geographic location,
“primary” aim of the study, median number of participants, type of
phytoestrogens, median duration of intervention, route of phytoes-
trogen administration, time since menopause onset, and women’s
health status (healthy vs. women with preexisting chronic disease/non-
healthy) were pre-specified as characteristics for assessment of het-
erogeneity and were evaluated using stratified analyses and random-
effects meta-regression, if 10 or more studies were included in the meta-
analysis [25]. To assess the influence of each individual study to the
overall estimates of the rest of the studies, leave-one-out sensitivity
analysis was performed iteratively by removing one study at a time to
confirm that the findings were not influenced by any single study.
Publication bias was evaluated through a funnel plot and asymmetry
was assessed using the Egger’s test. All tests were two-tailed and p-
values of 0.05 or less was considered as statistically significant. STATA
release 14 (Stata Corp, College Station, Texas) was used for all
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statistical analyses.
3. Results
3.1. Characteristics of included RCTs
Overall 5932 references were identified using the search strategy.
After initial screening based on titles and abstracts, the full texts of 92
articles were retrieved and evaluated further. As shown in Fig. 1, after
full text assessment, 69 studies were excluded due to inappropriate
study design, inappropriate population/exposure studies, or gender
specific estimates missing. The remaining 23 RCTs [15–20,26–43] were
included in the review and meta-analysis. In total 1880 postmenopausal
women (1130 in intervention arm and 750 in placebo arm) were in-
cluded in the meta-analysis of 23 RCTs. Six trials were done in Asia, 6 in
Europe, 5 in North America and 6 in South America. Most of the studies
were done among healthy women (n= 19), while four RCTs were
conducted in women with metabolic syndrome, type 2 diabetes (T2D),
sarcopenic obese, and one RCT in women with prehypertension. All
women included in current review were postmenopausal and on
average 4.19–15.9 years into menopause, and did not use MHT. The
follow-up ranged from 8 to 48 weeks, with majority of RCTs lasting for
24 weeks (n= 11). In nine included RCTs, the effect of phytoestrogen
supplementation on parameters of body composition was primarily
investigated, while the rest of RCTs investigated the other outcomes
(e.g. effect of phytoestrogen supplementation on bone mineral density,
menopausal symptoms relief), but reported baseline and end study data
on anthropometric parameters of interest. Detailed characteristics of
included RCTs are presented in Table 1.
3.2. Association between phytoestrogen supplementation and parameters of
body composition
Data from 18 RCTs, including 1692 postmenopausal women, con-
tributed to the meta-analysis on effects of phytoestrogen supple-
mentation on body weight. Consumption of any type of phytoestrogen
supplements, as compared to placebo, was not associated with sig-
nificant decrease in body weight in postmenopausal women [pooled
mean difference of changes: −0.14 kg (95%CI: −0.49 to 0.21)]
(Fig. 2), in subgroup analysis, a significant decrease in body weight
with overall phytoestrogens supplement use as compared to placebo
was found in healthy postmenopausal women [pooled mean difference
of changes: −0.28 kg (95%CI: −0.52 to −0.04)]. In contrast, phy-
toestrogen supplementation was associated with increased body weight
in postmenopausal women with preexisting health disorders (pre-
diabetes, T2D, prehypertension and hyperlipidemia), [pooled mean
difference of changes: 0.78 kg (95%CI: 0.53–1.03)] (Fig. 2).
Based on the findings of 18 RCTs, including 1456 postmenopausal
women, overall phytoestrogen supplementation was not associated
with BMI changes, [the pooled mean difference of BMI was 0.01 kg/m2
Fig. 1. Flowchart of studies included in this review.
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(95%CI: −0.14 to 0.16)] (Fig. 3). In subgroup analysis on health status,
the results remained similar, with no significant decrease in mean dif-
ference of BMI among healthy and postmenopausal women with pre-
existing health conditions (Fig. 3). When stratified by type of phy-
toestrogen supplements, a significant increase was observed in body
weight and BMI change with daidzein [pooled mean difference of
changes: 0.92 kg (95%CI: 0.24–1.59)] and [pooled mean difference of
changes: 0.35 kg/m2 (95%CI: 0.17–0.52] respectively. Moreover, a
significant decrease of body weight was found with isoflavone mix
supplements [pooled mean difference of changes: −0.24 Kg (95%CI:
−0.46 to −0.01)] (Table 2).
The data from 8 RCTs including 847 postmenopausal women con-
tributed to the meta-analysis on effects of phytoestrogen supple-
mentation on WHR. Pooled mean WHR change was slightly and sig-
nificantly decreased, [pooled mean difference of changes of was
−0.01 cm (95%CI: −0.01 to −0.006) (Fig. 4).
Data from 9 RCTs, including 824 postmenopausal women and 4
RCTs including 610 postmenopausal women investigated the associa-
tion between phytoestrogen supplementation and waist and hip cir-
cumference changes, respectively. Consumption of any type of phy-
toestrogen supplements, as compared to placebo, was not associated
with a reduction in changes of waist circumference and hip cir-
cumference [pooled mean differences of change were: 0.27 cm (95%CI:
–0.38 to 0.92) and 0.49 cm (95% CI –0.20 to 1.17)] (Supplemental
Figure 1). Furthermore, pooled mean differences based on 6 RCTs, in-
cluding 421 and 5 RCTs including 573 postmenopausal women showed
no association between overall phytoestrogen use and changes in the
body fat and percentage of body fat. Pooled mean difference of changes
were−0.23 kg (95%CI:−0.74 to 0.28) and−0.26% (95% CI−0.75 to
0.18), respectively (Supplemental Figure 2).
3.3. Assessments of bias, heterogeneity and sensitivity analysis
Two RCTs showed high risk of bias in two domains; however, for
most of the RCTs (n=21), the risk of bias could not be classified in one
or more domains (Supplemental Table 2). The four of seven meta-
analyses of RCTs showed high between-study heterogeneity, with an I2
estimate exceeding 75% and PQ statistic < 0.05, yet, in subgroup analysis
by the type of phytoestrogens status, the heterogeneity varied from 0 to
97.2%. In the current systematic review, as shown in the stratified
analyses, high heterogeneity might be attributed to the study quality,
differences in the methodology of trials and study location. Although I2
values varied across subgroup analysis, using “meta-regression
method”, it was not possible to explain the observed heterogeneity
made by any of parameters investigated (the “primary” goal of the
study, health status, median years since menopause, route of phytoes-
trogen administration, type of phytoestrogens, duration of the inter-
vention, number of study participants nor by study location or study
quality) (Table 1). However, when stratified by median number of trial
participants, in small RCTs with median number of participants ≤66
phytoestrogen supplementation was associated with significant de-
crease in body weight [pooled mean difference of changes −0.49 kg
(95%CI: −0.87 to −0.11)] (Table 2).
In a leave-one out sensitivity analysis, the pooled estimates were not
influenced by any single study included in the analyzes (Supplemental
Figure 3a–c). For the pooled analyses involving eight or more studies,
publication bias was assessed visually using Begg’s funnel plots. The
funnel plot for pooled analysis of body weight changes was non-
symmetrical with Egger’s p value of 0.005 indicating presence of pub-
lication bias. However, funnel plots for pooled analyses reporting
changes in BMI and WHR were approximately symmetrical with non-
significant Egger’s test estimates for all of these analyses (p values were
Fig. 2. The association between phytoestrogen supplementation and changes in body weight.
Pooled mean difference is based on 18 RCTs, including 1692 postmenopausal women (1006 in intervention arm and 686 in control arm).
WMD, weighted mean different. Mean difference refers to mean difference of changes between treatment groups. Size of data markers are proportional to the inverse
of the variance of the effect estimate. P value comes from Q statistics.
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0.19 and 0.97 respectively) (Fig. 5).
4. Discussion
4.1. Summary of evidence
In this systematic review and meta-analysis, phytoestrogen supple-
mentation (compared to placebo and followed by usual diet) was as-
sociated with a slight decrease in WHR, and was not associated with
changes in body weight, BMI, WC, HC, FM and PBF in postmenopausal
women. There was also, an indication that type of phytoestrogens, and
health status may play a role in modifying the effect of phytoestrogens
in reducing body weight. For instance, a significant decrease in changes
of body weight was observed among healthy postmenopausal women
and when isoflavone mixture supplements were used. Contrary, body
weight was increased in women with underlying metabolic disorders
and/or with use of isoflavones rich in daidzein. Furthermore, trials with
small sample size showed improved body weight effects in women as-
sociated with phytoestrogens, but this effect was not observed in trials
with larger samples.
4.2. Interpretation of findings
In contrast to our findings, a meta-analysis published in 2013, re-
ported a significant decrease in body weight with soy isoflavone sup-
plementation [pooled mean difference of −0.52 kg (95%CI: −0.89 to
−0.134)] [21]. Although, we did not observe overall significant asso-
ciations between phytoestrogen supplementation and improvements in
body composition parameters, we concluded that type of phytoestro-
gens and underlying metabolic status of women may play a role in
modifying the effectiveness of phytoestrogens in reducing the body
weight. There may be several factors that may have yield the differ-
ences in our findings on phytoestrogen supplementation and changes in
body weight in comparison with previous review. First, we included all
types of phytoestrogen supplements, while the prior meta-analysis in-
vestigated solely the effect of soy derived phytoestrogens and not the
other types of phytoestrogen supplements (e.g. daidzein/genistein en-
riched formulations, soy products). Second, they included only non-
Asian postmenopausal women, while in the current review seventeen
non-Asian trials (European, North and South American) and six of Asian
trials were included. Finally, the findings of the previous review were
based on 9 RCTs and 578 postmenopausal women (272 in intervention
trial and 256 in control arm) while we included 23 RCTs and 1880
postmenopausal women (1130 in intervention arm and 750 in placebo
arm). Overall, there are some indications that certain types of phy-
toestrogens may be beneficial in reducing body weight, these findings
are supported with experimental data and merit further investigation.
4.3. Biological mechanisms/plausibility
Adipose tissue is highly responsive to estrogen, and both, human
and mouse fat tissue express estrogen receptor (ER) α and ERβ [44].
The mechanisms by which dietary soy and phytoestrogens may reduce
adiposity are not fully understood. Phytoestrogens may affect the body
composition directly binding estrogen receptors (mainly ER α), by
mediating the action of hormones thought to be involved in the reg-
ulation of body composition (adiponectin, ghrelin, insulin, leptin) or by
altering the metabolic activity of adipocytes [45]. Indeed, experimental
studies suggested that phytoestrogens could be useful in treating or
preventing increased adiposity after menopause onset [46]. Findings
Fig. 3. The association between phytoestrogen intake and changes in BMI.
Pooled mean difference is based on 18 RCTs, including 1456 postmenopausal women (835 in intervention arm and 603 in control arm).
WMD, weighted mean different. Mean difference refers to mean difference of changes between treatment groups. Size of data markers are proportional to the inverse
of the variance of the effect estimate. P value comes from Q statistics.
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from animal studies reported that fat abundance observed in mice ex-
posed to dietary phytoestrogens correlated with enzymes which could
be the key regulators of fatty acid oxidation (AMP-activated protein
kinase and Acetyl-CoA carboxylase) [47]. Ovariectomized mice fed
with a soy-rich diet have reduced weight and had less adipose deposi-
tion than those fed on a soy-free diet [48]. Genistein as the most
abundant phytoestrogen in soy food, was extensively studied. Indeed,
genistein reversed the truncal fat accumulation in ovariectomized ro-
dent models [44,46]. Moreover, in vitro studies using isolated rat
adipocytes genistein was found to inhibit the conversion of acetate into
lipids, inhibit basal lipogenesis, inhibit the conversion of glucose to
lipids more than estradiol, and increase basal lipolysis [49]. Although,
genistein may cause adipose changes in mice in concentrations that are
within the range of those reported in humans under various nutritional
conditions, it is not clear whether genistein could have antilipogenic
effects in humans. [44].
Subgroups by Study Characteristics Number of studies 1Difference, Mean (95% CI) 2For heterogeneity 3P value for heterogeneity
Phytoestrogen use and mean body weight change
aPrimary study goal of the RCT Body composition 7 −0.04 (−0.68; 0.60) 68.7% 0.59
Other 11 −0.21 (−0.64; 0.23) 62.3%
bMedian years since menopause onset ≤4.1 years 4 −0.23 (−0.6; 0.14) 16.5% 0.87
> 4.1 years 8 0.07 (−0.51; 0.64) 68.2%
Unknown 6 −0.29 (−0.63; 0.04) 0%
cRoute of administration Tablet/capsule 10 −0.17 (−0.82; 0.47) 76.4% 0.52
Diet 8 −0.17 (−0.42; 0.07) 0%
dIntervention type Soy products 6 −0.49 (−1.21;0.23) 65.4% 0.83
Isoflavone mix 10 −0.24(−0.46; −0.01) 0%
Daidzein 2 0.92 (0.24; 1.59) 55%
eMedian number of study participants ≤66 women 9 −0.49 (−0.87; −0.11) 0% 0.22
> 66 women 9 0.11 (−0.31; 0.52) 75.2%
fIntervention duration ≤24 weeks 15 −0.10 (−0.51; 0.30) 69.5% 0.9
> 24 weeks 3 −0.32 (−1.02; 0.37) 53.2%
gLocation Asia 7 0.22 (−0.25; 0.69) 76.8% 0.48
Europe 4 −0.35 (−0.78; 0.07) 11%
North America 4 −0.6 (−1.44; 0.24) 0%
South America 3 −0.48 (−1.13; 0.17) 0%
hRisk of bias High 2 −0.85 (−1.93; 0.22) 0% 0.39
Low to medium 16 −0.09 (−0.45; 0.27) 69.6%
Phytoestrogen use and mean Body Mass Index change
aPrimary study goal of the RCT Body composition 7 0.002 (−0.26;0.44) 74.4% 0.49
Other 11 0.01(−0.13; 0.13) 24.6%
bMedian years since menopause onset ≤7.45 years 8 −0.03 (−0.2; 0.14) 53.9% 0.51
> 7.45 years 4 −0.08 (−0.5; 0.33) 0%
Unknown 6 −0.16(−0.40; 0.08) 0%
cRoute of administration Tablet/capsule 10 0.03 (−0.17; 0.23) 47.9% 0.23
Diet 8 −0.02 (−0.26; 0.22) 73.1%
dIntervention type Soy products 5 −0.15 (−0.76; 0.47) 68.3% 0.64
Isoflavone mix 9 0.01 (−0.10; 0.11) 0%
Daidzein 2 0.35 (0.17; 0.52) 25.1%
Genistein 1 −0.17 (−2.87, −2.53) NA
eMedian number of study participants ≤60 women 9 0.07 (−0.2; 0.35) 36% 0.19
> 60 women 9 −0.02 (−0.21; 0.17) 75.2%
fIntervention duration ≤20 weeks 9 −0.03 (−0.24; 0.19) 74% 0.31
> 20 weeks 9 0.05 (−0.16; 0.26) 38.1%
gLocation Asia 5 0.01 (−0.24;0.26) 82.7% 0.48
Europe 4 −0.06 (−0.51; 0.39) 38.2%
North America 5 0.09 (−0.13; 0.31) 0%
South America 4 0.1 (−0.44; 0.63) 69.6%
hRisk of bias High 2 0.18 (−0.06; 0.41) 0% 0.81
Low to medium 16 −0.01 (−0.17; 0.16) 65.8%
1 Mean difference refers to mean difference of changes between treatment groups in body weight and BMI (subjects using phytoestrogens as compared with the
subjects from control/placebo group).
2 For heterogeneity was calculated using fixed- effects models.
3 P value for heterogeneity was evaluated using random-effects meta-regression (in case that more than 8 studies was meta-analyzed).
a Some of RCTs investigated the effect of phytoestrogens on body composition, the others investigated other outcomes but they reported changes in anthropo-
metric parameters at baseline and at the end of the studies.
b Median years since menopause, number of years since menopause onset, unknown: no information.
c Route of administration includes tablets/capsules use and other routes of administration (shake, powder, flower).
d Type of phytoestrogens includes use of soy derived isoflavones/soy protein+ isoflavones, extracts of soy isoflavones/isoflavone mixture, daidzein/genistein
supplements.
e Number of study participants: median number of participants calculated for each outcome separately.
f Intervention duration: median intervention duration was calculated for each outcome separately.
g Location refers to study location, studies done in Asian ground and the other location (studies done in Europe, America and Australia).
h Studies are judged to be at lower high risk of bias based on criteria to evaluate random sequence generation, allocation concealment, blinding of participants/
personnel and outcome assessment, incomplete outcome data and selective reporting.
Table 2
The subgroup analyses by study characteristics.
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4.4. Strengths and limitations
To our knowledge, this is the first systematic review and meta-
analysis including 1880 postmenopausal women to comprehensively
address the associations of phytoestrogens with anthropometric para-
meters in women. Only clinical trials investigating phytoestrogen sup-
plementation following usual/regular diet were included; therefore,
studies that combined phytoestrogen supplementation with hypocaloric
diets or in combination with exercise were not taken into consideration.
Furthermore, we included clinical trials that did not “primary” in-
vestigate body composition but have reported outcomes of interest at
baseline as well as at the end of trial. In subgroup analysis, those studies
which did not primary investigate body composition were excluded and
the results remained stable.
However, there are several limitations that need to be mentioned.
First, in this study, we found a trend for the possibility of publication for
studies investigating body weight changes. Despite the findings of
funnel plots and Egger’s test, the estimates could indicate minimal
publication bias for RCTs investigating BMI and WHR, these approaches
are potentially limited by their qualitative nature; therefore, findings on
BMI and WHR may have been affected by publication bias as well.
Second, the quality of included RCTs in this review was limited because
the majority of included RCTs could not be classified in one or more
domains, which might have contributed to the heterogeneity that has
been observed in the meta-analyses presented in this study (quality and
composition of supplements). Furthermore, in included trials women
were on average 4.19–15.9 years into menopause. Early post-
menopausal period is characterized by pronounced changes in body
composition, with an increase in both overall and intra-abdominal
adiposity [50]. In fact, in subgroup analysis by median time since
menopause, pooled effect on body weight, although non-significant,
was larger and in opposite direction compared to women with longer
menopause duration. In addition, only four RCTs with more than 100
participants and only four RCT with a duration of the intervention of
≥6 months were found, which might undermine the precision of the
estimates and may limit the understanding of long-term effects of
phytoestrogen supplementation on body composition in women. Con-
sidering these observations, the overall results of this study should be
interpreted with caution. Finally, most of trials were published before
2013, with only one recent RCT investigating this topic after 2013.
Thus, there may be some differences in formulation and quality of
supplements of recent data compared to supplements was used ≥5
years ago.
Fig. 4. The association between phytoestrogen supplementation and changes in waist to hip ratio.
Pooled mean difference is based on 8 RCTs, including 847 postmenopausal women (510 in intervention arm and 337 in control arm).
WMD, weighted mean different. Mean difference refers to mean difference of changes between treatment groups. Size of data markers are proportional to the inverse
of the variance of the effect estimate. P value comes from Q statists.
Fig. 5. Funnel plots for RCTs included in the main analysis.
The dotted lines show 95% confidence intervals around the overall summary estimate calculated using a random effect model.
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